Sweden's Stille Q1 net sales rise 38.5% on strong demand

Stille AB

24/04/2026 07:11

Overview

Sweden surgical instruments maker's Q1 net sales rose 38.5% yr/yr, organic growth 18.6%

Adjusted EBITDA increased to SEK 38.5 mln from SEK 25.2 mln yr/yr

Company cites strong demand and improved product availability for growth

Outlook

Company continues to see strong demand for its products and improved product availability

Stille says it is well positioned to pursue selective acquisitions to build the group

Result Drivers

STRONG DEMAND - Co said strong demand for its products drove Q1 growth

PRODUCT AVAILABILITY - Co said improved product availability contributed to revenue growth

Company press release: ID:nMFN9wkhJb

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 179.10 mln
SEK 156 mln (2 Analysts)
Q1 Adjusted EBITDA
SEK 38.50 mln
Q1 Adjusted EBIT
SEK 30 mln
Q1 EBIT
SEK 30 mln
Q1 EBITDA
SEK 38.50 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Stille AB is SEK240.00, about 4.3% above its April 23 closing price of SEK230.00

The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 19 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)